339 related articles for article (PubMed ID: 34020790)
21. [Recent progress and prospect in oligonucleotide therapeutics].
Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T
Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142
[TBL] [Abstract][Full Text] [Related]
22. Safety of antisense oligonucleotide and siRNA-based therapeutics.
Chi X; Gatti P; Papoian T
Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
[TBL] [Abstract][Full Text] [Related]
23. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
[TBL] [Abstract][Full Text] [Related]
24. Antisense drug discovery and development technology considered in a pharmacological context.
Crooke ST; Liang XH; Crooke RM; Baker BF; Geary RS
Biochem Pharmacol; 2021 Jul; 189():114196. PubMed ID: 32800852
[TBL] [Abstract][Full Text] [Related]
25. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.
Bennett CF; Swayze EE
Annu Rev Pharmacol Toxicol; 2010; 50():259-93. PubMed ID: 20055705
[TBL] [Abstract][Full Text] [Related]
26. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases.
Pandey M; Ojha D; Bansal S; Rode AB; Chawla G
Mol Aspects Med; 2021 Oct; 81():101003. PubMed ID: 34332771
[TBL] [Abstract][Full Text] [Related]
27. Antisense applications for biological control.
Pan WH; Clawson GA
J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
[TBL] [Abstract][Full Text] [Related]
28. Polyamine-oligonucleotide conjugates: a promising direction for nucleic acid tools and therapeutics.
Menzi M; Lightfoot HL; Hall J
Future Med Chem; 2015; 7(13):1733-49. PubMed ID: 26424049
[TBL] [Abstract][Full Text] [Related]
29. Selective tissue targeting of synthetic nucleic acid drugs.
Seth PP; Tanowitz M; Bennett CF
J Clin Invest; 2019 Mar; 129(3):915-925. PubMed ID: 30688661
[TBL] [Abstract][Full Text] [Related]
30. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
Taniguchi H; Suzuki Y; Imai K; Adachi Y
Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
[TBL] [Abstract][Full Text] [Related]
31. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
Toub N; Malvy C; Fattal E; Couvreur P
Biomed Pharmacother; 2006 Nov; 60(9):607-20. PubMed ID: 16952435
[TBL] [Abstract][Full Text] [Related]
32. In-silico study of antisense oligonucleotide antibiotics.
Chen ES; Ho ES
PeerJ; 2023; 11():e16343. PubMed ID: 38025700
[TBL] [Abstract][Full Text] [Related]
33. Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications.
Benizri S; Gissot A; Martin A; Vialet B; Grinstaff MW; Barthélémy P
Bioconjug Chem; 2019 Feb; 30(2):366-383. PubMed ID: 30608140
[TBL] [Abstract][Full Text] [Related]
34. Endosomal Escape of Antisense Oligonucleotides Internalized by Stabilin Receptors Is Regulated by Rab5C and EEA1 During Endosomal Maturation.
Miller CM; Wan WB; Seth PP; Harris EN
Nucleic Acid Ther; 2018 Apr; 28(2):86-96. PubMed ID: 29437530
[TBL] [Abstract][Full Text] [Related]
35. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides.
Delihas N
Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic antisense oligonucleotides for movement disorders.
Doxakis E
Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
38. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs.
Takakusa H; Iwazaki N; Nishikawa M; Yoshida T; Obika S; Inoue T
Nucleic Acid Ther; 2023 Apr; 33(2):83-94. PubMed ID: 36735616
[TBL] [Abstract][Full Text] [Related]
39. Oligonucleotide delivery: a patent review (2010 - 2013).
Grijalvo S; Aviñó A; Eritja R
Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Antisense Oligonucleotides Are Coming of Age.
Bennett CF
Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
